These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 32967471)

  • 21. Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: challenge and outlook.
    Sonomoto K; Tanaka Y
    Expert Rev Clin Immunol; 2023; 19(11):1325-1342. PubMed ID: 37578325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.
    Hernández-Cruz B; Otero-Varela L; Freire-González M; Busquets-Pérez N; García González AJ; Moreno-Ramos M; Blanco-Madrigal JM; Manrique-Arija S; Perez-Pampin E; Ruiz-Montesino D; Sánchez-Alonso F; Sanchez-Piedra C; Castrejón I;
    Ann Rheum Dis; 2024 Aug; 83(9):1189-1199. PubMed ID: 38594056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
    Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
    Amstad A; Papagiannoulis E; Scherer A; Rubbert-Roth A; Finckh A; Mueller R; Dudler J; Möller B; Villiger PM; Schulz MMP; Kyburz D
    Rheumatology (Oxford); 2022 Dec; 62(1):89-97. PubMed ID: 35579338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis.
    Alciati A; Di Carlo M; Siragusano C; Palumbo A; Masala IF; Atzeni F
    Expert Opin Biol Ther; 2022 Oct; 22(10):1311-1322. PubMed ID: 36168970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.
    Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K
    BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Rheumatoid arthritis: Appraisement of the new security warnings for JAK-inhibitors].
    Fiehn C
    Dtsch Med Wochenschr; 2024 Mar; 149(6):326-330. PubMed ID: 38412990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.
    Yoshida S; Miyata M; Suzuki E; Kanno T; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    Front Immunol; 2023; 14():1267749. PubMed ID: 37868999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
    Kerrigan SA; McInnes IB
    Curr Rheumatol Rep; 2018 Nov; 20(12):83. PubMed ID: 30406861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
    Jegatheeswaran J; Turk M; Pope JE
    Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Janus Kinase Inhibitors: Safety in Patients With Psoriatic Arthritis.
    Nash P
    J Rheumatol; 2022 Jun; 49(6 Suppl 1):44-47. PubMed ID: 35293326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK Inhibitors: What Is New?
    Reddy V; Cohen S
    Curr Rheumatol Rep; 2020 Jul; 22(9):50. PubMed ID: 32700001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy.
    Kiełbowski K; Plewa P; Bratborska AW; Bakinowska E; Pawlik A
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.
    Angelini J; Talotta R; Roncato R; Fornasier G; Barbiero G; Dal Cin L; Brancati S; Scaglione F
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32635659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
    Huss V; Bower H; Hellgren K; Frisell T; Askling J; ;
    Ann Rheum Dis; 2023 Jul; 82(7):911-919. PubMed ID: 36868796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Start RA treatment - Biologics or JAK-inhibitors?
    Caporali R; Germinario S; Kacsándi D; Choy E; Szekanecz Z
    Autoimmun Rev; 2024 Jan; 23(1):103429. PubMed ID: 37634678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.
    Taylor PC; Choy E; Baraliakos X; Szekanecz Z; Xavier RM; Isaacs JD; Strengholt S; Parmentier JM; Lippe R; Tanaka Y
    Rheumatology (Oxford); 2024 Feb; 63(2):298-308. PubMed ID: 37624925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world comparative study of drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis.
    Saito K; Yoshida S; Ebina H; Miyata M; Suzuki E; Kanno T; Sumichika Y; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    PLoS One; 2024; 19(7):e0306714. PubMed ID: 38990897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study.
    Venerito V; Stefanizzi P; Cantarini L; Lavista M; Galeone MG; Di Lorenzo A; Iannone F; Tafuri S; Lopalco G
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
    Sung YK; Lee YH
    Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.